Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Genomic Studies in Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorders Show Alterations That Differ from Aggressive CD30-Positive T-Cell Lymphomas

Joo Y. Song, Weiwei Zhang, Michi M. Shinohara, Kord Honda, Christiane Querfeld, Julia Davidson, Krystie Chew, Lu Chen, Alexandra Hristov, Jasmine Zain, Anamarija M. Perry, Wing Chung Chan, Farah R Abdulla

Blood (2024) 144 (Supplement 1): 6225.

https://doi.org/10.1182/blood-2024-206611

Published: 2024

Journal Articles

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1742.1.

https://doi.org/10.1182/blood-2024-198727

Published: 2024

Journal Articles

Identification of High-Efficiency β-Catenin Protein Degradation As Critical Vulnerability in B-Cell Malignancies

Kadriye Nehir Cosgun, Mark E Robinson, Nikol Agadzhanian, Zhangliang Cheng, Salim Oulghazi, Philipp Berning, David Fonseca-Arce, Kohei Kume, Jake Fontaine, Lai N Chan, Jaewoong Lee, Fang Yu, Zhijian Qian, Joo Y. Song, Wing Chung Chan, Jianjun Chen, Mark M Taketo, Hilde Schjerven, Markus Müschen

Blood (2024) 144 (Supplement 1): 4125.

https://doi.org/10.1182/blood-2024-208125

Published: 2024

Journal Articles

Integrating Metabolomics and Molecular Pathways to Uncover Therapeutic Vulnerabilities in Richter's Transformation

Prajish Iyer, Brian Jiang, Girish Venkataraman, Joo Y. Song, Wing Chung Chan, Tanya Siddiqi, Steven T. Rosen, Alexey Danilov, Antje Gohla, Lili Wang

Blood (2024) 144 (Supplement 1): 760.

https://doi.org/10.1182/blood-2024-199843

Published: 2024

Journal Articles

Complementary Roles of DNMT3A and TET2 KO in Sculpting CD4-T Cells for Sustained Proliferation without Exhaustion to Promote Lymphomagenesis

Ruimeng Yang, Xuxiang Liu, Jibin Zhang, Abdul Rouf Mir, Waseem Gul Lone, Yuping Li, Krystie Chew, Claire Wu, Jasmine Zain, Joo Y Song, Javeed Iqbal, Wing Chung Chan

Blood (2024) 144 (Supplement 1): 1362.

https://doi.org/10.1182/blood-2024-211750

Published: 2024

Journal Articles

An Llmpp Study: Genomic Characterization of Novel PTCL- Biological Subtypes Reveal Distinctive Therapeutic Vulnerabilities

Blood (2024) 144 (Supplement 1): 456.

https://doi.org/10.1182/blood-2024-209396

Published: 2024

Journal Articles

B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements

Blood (2024) 144 (Supplement 1): 453.

https://doi.org/10.1182/blood-2024-203258

Published: 2024

Journal Articles

HIV-Associated Diffuse Large B-Cell Lymphoma Shows Different Genomic Patterns between EBV-Positive and EBV-Negative Tumors

Blood (2024) 144 (Supplement 1): 2976.

https://doi.org/10.1182/blood-2024-206279

Published: 2024

Journal Articles

The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

Andrew L. Feldman, Guangzhen Hu, Surendra Dasari, Lisa M. Rimsza, David W. Scott, Jimena B. Gimenez, Farah M. Salama, Min Shi, Elías Campo, Wing Chung Chan, James R. Cook, Giorgio Inghirami, Elaine S. Jaffe, Ryan Morin, Phillipp W. Raess, Andreas Rosenwald, Kerry J. Savage, Louis M. Staudt, George W. Wright, Catalina Amador, Jan Delabie, Timothy C. Greiner, Javeed Iqbal, Laura K. Hilton, Sarah L. Ondrejka, German Ott, Stefania Pittaluga, Graham W. Slack, Susan L. Slager, Joo Y. Song, Hao-Wei Wang, Ahmed A. Aljudi, Stephen M. Ansell, Carlos Barrionuevo, James R. Cerhan, Jennifer R. Chapman-Fredricks, Weina Chen, Laurence de Leval, Alejandro A. Gru, David L. Jaye, Liuyan Jiang, Brad S. Kahl, Kennosuke Karube, Young Hyeh Ko, Eric Mou, Matthew J. Maurer, L. Jeffrey Medeiros, Roberto N. Miranda, Naoki Oishi, Perry M. Anamarija, Akira Satou, Xueju Wang, Ryan A. Wilcox, Xiaojun Wu, Tadashi Yoshino, Yu Zeng

Blood (2024) 144 (Supplement 1): 2974.

https://doi.org/10.1182/blood-2024-202410

Published: 2024

Journal Articles

Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and MYC Rearrangement- an L.L.M.P.P. Study

Blood (2024) 144 (Supplement 1): 231.

https://doi.org/10.1182/blood-2024-208880

Published: 2024

Journal Articles

Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

Marissa Morales Del Real, John H. Baird, Lu Chen, Joo Y. Song, Xiuli Wang, Swetha Kambhampati, Alan Macias, Emanuela C Marcucci, Soungchul Cha, Zhenyuan Dong, Teresa Kim, Baishakhi Barva, Sandrine Puverel, Qing Liu-Michael, Hazel Ting-Ying Cheng, Stephen J. Forman, Larry W. Kwak, Lihua E. Budde

Blood (2024) 144 (Supplement 1): 3127.

https://doi.org/10.1182/blood-2024-198416

Published: 2024

Journal Articles

Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma

Blood (2024) 144 (Supplement 1): 4361.

https://doi.org/10.1182/blood-2024-201598

Published: 2024

Journal Articles

Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

Blood (2024) 144 (5): 525–540.

https://doi.org/10.1182/blood.2024024251

Published: 2024

Includes: Supplemental data

Journal Articles

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

James K. Godfrey, Lei Gao, Geoffrey Shouse, Joo Y. Song, Stacy Pak, Brian Lee, Bihong T. Chen, Avyakta Kallam, John H. Baird, Guido Marcucci, Lucy Ghoda, Stephanie Vauleon, Alexey V. Danilov, Alex F. Herrera, Larry W. Kwak, Lihua E. Budde

Blood (2024) 144 (4): 457–461.

https://doi.org/10.1182/blood.2024024168

Published: 2024

Includes: Supplemental data

Journal Articles

Glycerolipid Metabolism Via the MGA-MYC-NME1-PGP Axis As a Key Regulator of Oxidative Phosphorylation in Richter's Transformation

Prajish Iyer, Brian Jiang, Girish Venkataraman, Joo Y Song, Tanya Siddiqi, Steven T. Rosen, Alexey Danilov, Lili Wang

Blood (2023) 142 (Supplement 1): 79.

https://doi.org/10.1182/blood-2023-179427

Published: 2023

Journal Articles

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Blood (2023) 142 (Supplement 1): 610.

https://doi.org/10.1182/blood-2023-180107

Published: 2023

Journal Articles

Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study

L. Elizabeth Budde, Marissa Morales Del Real, John H. Baird, Lu Chen, Joo Y. Song, Swetha Kambhampati, Alan Macias, Teresa Kim, Sylvia Dulan, Baishakhi Barva, Sandrine Puverel, Katrin Tiemann, Hazel Ting-Ying Cheng, Stephen J. Forman, Larry W. Kwak

Blood (2023) 142 (Supplement 1): 221.

https://doi.org/10.1182/blood-2023-183032

Published: 2023

Journal Articles

Evaluation of a Prognostic 23-Gene Expression Panel in a Set of 390 Multiethnic Hodgkin Lymphoma Patients

Blood (2023) 142 (Supplement 1): 4379.

https://doi.org/10.1182/blood-2023-182906

Published: 2023

Journal Articles

Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma Enrolled on SWOG S1826

Blood (2023) 142 (Supplement 1): 181.

https://doi.org/10.1182/blood-2023-180114

Published: 2023

Journal Articles

Mechanistic Elucidation of the Tumor-Promoting Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in B-Cell Receptor Signaling in Mantle Cell Lymphoma

Serene Xavier, Vivian Nguyen, Vishal Khairnar, An Phan, Lu Yang, Michael Nelson, Elizabeth Tseng, Aimin Li, Joo Y Song, Dennis D. Weisenburger, Wing C. Chan, Markus Müschen, Vu N. Ngo

Blood (2023) 142 (Supplement 1): 720.

https://doi.org/10.1182/blood-2023-175064

Published: 2023

NARROW

Genomic Studies in Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorders Show Alterations That Differ from Aggressive CD30-Positive T-Cell Lymphomas

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Identification of High-Efficiency β-Catenin Protein Degradation As Critical Vulnerability in B-Cell Malignancies

Integrating Metabolomics and Molecular Pathways to Uncover Therapeutic Vulnerabilities in Richter's Transformation

Complementary Roles of DNMT3A and TET2 KO in Sculpting CD4-T Cells for Sustained Proliferation without Exhaustion to Promote Lymphomagenesis

An Llmpp Study: Genomic Characterization of Novel PTCL- Biological Subtypes Reveal Distinctive Therapeutic Vulnerabilities

B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements

HIV-Associated Diffuse Large B-Cell Lymphoma Shows Different Genomic Patterns between EBV-Positive and EBV-Negative Tumors

The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and MYC Rearrangement- an L.L.M.P.P. Study

Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma

Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

Glycerolipid Metabolism Via the MGA-MYC-NME1-PGP Axis As a Key Regulator of Oxidative Phosphorylation in Richter's Transformation

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study

Evaluation of a Prognostic 23-Gene Expression Panel in a Set of 390 Multiethnic Hodgkin Lymphoma Patients

Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma Enrolled on SWOG S1826

Mechanistic Elucidation of the Tumor-Promoting Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in B-Cell Receptor Signaling in Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only